Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10997472 | 0.87 | GRM5 (0.53) | GRM5ALDH1A1MAPTTSHRL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL30821440 | 0.84 | CHIT1 (0.43) | GRM5ADAM17ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL967014 | 0.82 | GRM5 (0.46) | GRM5ALDH1A1MAPTTSHRL3MBTL1 | |
| SCHEMBL28091793 | 0.79 | GRM5 (0.47) | GRM5ALDH1A1MAPTTSHRL3MBTL1 | |
| SCHEMBL968474 | 0.79 | GRM5 (0.47) | GRM5ALDH1A1MAPTTSHRL3MBTL1 | |
| SCHEMBL14085329 | 0.79 | CYP1A2 (0.49) | GRM5ALDH1A1MAPTTSHRL3MBTL1 | |
| SCHEMBL27324689 | 0.79 | GRM5 (0.47) | GRM5ALDH1A1MAPTTSHRL3MBTL1 | |
| SCHEMBL15147552 | 0.77 | ADAM17 (0.49) | ADAM17ALDH1A1MAPTTSHRL3MBTL1 | |
| SCHEMBL28546126 | 0.77 | GRM5 (0.54) | GRM5ALDH1A1MAPTMEN1CYP1A2 | |
| SCHEMBL17188595 | 0.77 | GRM5 (0.46) | GRM5ALDH1A1MAPTTSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-115362003-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2022-11-18 | — | — | CN | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| CN-110467572-B | Synthetic method of 3-sulfonyl quinoline derivative | 温州大学 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| US-8470813-B2 | Thiazoline and oxazoline derivatives and their methods of use | ABBVIE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20100190776-A1 | Thiazoline and Oxazoline Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-07-29 | — | — | US | disclosed |
| US-7683084-B2 | Thiazoline and oxazoline derivatives and their methods of use | ABBOTT LABORATORIES (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080177085-A1 | Process for the Synthesis of a CPLA2 Inhibitor | DEHNHARDT CHRISTOPH M | 2008-07-24 | — | — | US | disclosed |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-20 | — | — | US | disclosed |
| US-7342119-B2 | Process for the synthesis of a CPLA2 inhibitor | WYETH HOLDINGS CORPORATION | 2008-03-11 | — | — | US | disclosed |
| US-20050070723-A1 | Process for the synthesis of a CPLA2 inhibitor | WYETH HOLDINGS CORPORATION (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | GRM5 2354/4885ADAM17 3788/4885ALDH1A1 4095/4885 |
| US-20050070723-A1 | Process for the synthesis of a CPLA2 inhibitor | PLAA, PLA2G4A, PLA2G12A | GRM5 2331/4885ADAM17 1642/4885ALDH1A1 3682/4885 |
| US-20080177085-A1 | Process for the Synthesis of a CPLA2 Inhibitor | PLAA, PLA2G4A, PLA2G12A | GRM5 2331/4885ADAM17 1642/4885ALDH1A1 3682/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | GRM5 2354/4885ADAM17 3788/4885ALDH1A1 4095/4885 |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | GRM5 2354/4885ADAM17 3788/4885ALDH1A1 4095/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | GRM5 2354/4885ADAM17 3788/4885ALDH1A1 4095/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | GRM5 2354/4885ADAM17 3788/4885ALDH1A1 4095/4885 |
| US-20100190776-A1 | Thiazoline and Oxazoline Derivatives and Their Methods of Use | OXA1L, CYP3A7, ABAT | GRM5 834/4885ADAM17 1576/4885ALDH1A1 254/4885 |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | OXA1L, CYP3A7, ABAT | GRM5 834/4885ADAM17 1576/4885ALDH1A1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.